
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
The American Journal of Managed Care
over 23 years ago
Pathophysiology and Management of Neurocardiogenic Syncope




